Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IGV 001

Drug Profile

IGV 001

Alternative Names: IGF-1R antisense therapy; IGF-1R/AS ODN; IGV-001; Insulin growth factor receptor type 1 antisense therapy; Type 1 insulin growth factor receptor antisense therapy

Latest Information Update: 27 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Thomas Jefferson University
  • Developer Imvax; Thomas Jefferson University
  • Class Antineoplastics; Antisense oligonucleotides; Cancer vaccines; Immunotherapies; Tumour cell vaccines
  • Mechanism of Action CD4-positive T-lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Preclinical Solid tumours

Most Recent Events

  • 22 May 2024 IGV 001 receives Fast Track designation for Glioblastoma [SC,Implant] (First-line therapy) in USA
  • 22 May 2024 Imvax completes enrolment in its phase II trial Glioblastoma (Combination therapy, Late-stage disease, First-line therapy) in USA (SC) (NCT04485949)
  • 28 Oct 2023 No recent reports of development identified for phase-I development in Glioblastoma(First-line therapy) in USA (SC, Implant)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top